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Hepatitis C virus infection among kidney transplant recipients. The
extent of hepatitis C virus (HCV) infection among kidney recipients was
investigated in 67 patients by testing for anti-HCV paired serum
samples, collected at time of transplantation and during follow-up
(average 32 20 months). Prevalence of anti-HCV at transplant time
was 48%, and was related to the time on dialysis and to the amount of
blood transfusions. Following transplantation, nine (28%) seropositive
patients lost anti-HCV and five (14%), previously seronegative, sero-
converted. Anti-HCV was found to be positive in 92% of the patients
with chronic liver disease who were on hemodialysis, but in 56% in
kidney recipients with chronic hepatitis. Anti-HCV was positive in 50%
of patients with resolving hepatitis before transplantation, but only in
21% of those with acute hepatitis following transplantation, This study
confirms the high risk of HCV infection among hemodialysis and kidney
recipient populations, and also that HCV is closely related with the
length of time the patient is on hemodialysis as well as the number of
blood units transfused. HCV is the main cause of acute and chronic
liver disease in hemodialysis patients and of chronic liver disease in
kidney recipients, but does not clearly influence the survival of the
allograft nor that of patients.
The majority of clinical studies on liver disease in hemodial-
ysis patients and in recipients of kidney transplantation deal
with the role of hepatitis B virus (HBV) infection [1—8] and
azathioprine toxicity [9—11]. The responsibility of non-A, non-B
hepatitis virus has been suggested on epidemiologic grounds
[12—14], but never demonstrated due to the lack of markers for
such a virus. Cloning of the hepatitis C virus (HCV), the main
agent for non-epidemic non-A, non-B hepatitis, and the expres-
sion of a non-structural protein of this virus have permitted the
development of a test to detect circulating antibodies to this
protein (anti-HCV), which are considered to be evidence of
actual or recent HCV infection [15, 16].
Preliminary surveys on hemodialysis patients have shown a
prevalence for anti-HCV of between 15 to 30% [17—21], similar
to that shown in a report on kidney recipients [22]. We studied
a cohort of kidney recipients to establish the prevalence and
persistence of anti-HCV, and to analyze their possible associ-
ation with risk factors and the development of liver disease.
Methods
Patients
We studied 67 consecutive kidney transplant patients attend-
ing the out-patient clinic of the Renal Transplantation Unit
during a two week period in November 1989. Eligibility criteria
for this study were the availability for anti-HCV testing of a
serum sample obtained at the time of transplantation and a
follow-up period of more than six months post-transplantation.
All patients had been transplanted between 1983 and 1989, and
the average follow-up was 32 20 months. Patients were 15 to
64 years of age (mean: 42 years). There were 48 men and 19
women. Fifty-nine additional kidney recipients attended the
out-patient clinic during the period of study, but there were not
included because the basal serum sample was not available for
anti-HCV testing. Male-to-female ratio, mean age, average
follow-up and prevalence of anti-HCV in the serum collected
after transplantation of patients included and not included were
virtually identical.
Immunosuppression consisted of cyclosporine as monother-
apy if post-transplant diuresis was present, and triple therapy
[azathioprine, prednisone and antilymphocytic serum (ALS)],
in the event of acute tubular necrosis. Rejection episodes were
treated with bolus of methyl-prednisolone, and ALS or OK-T3
monoclonal antibody if necessary.
Paired serum samples collected from each patient at trans-
plant time and at follow-up visits were stored frozen until assay,
and had not previously been thawed. Anti-HCV was tested in
duplicate with an enzyme-linked immunosorbent assay
(ELISA; Ortho Diagnostic Systems, Ranitan, New Jersey,
USA) according to the manufacturer's instructions. Samples
were considered reactive when the mean optical density (OD)
reading/cut-off ratio (ELISA ratio) was higher than I. To
control the specificity of the ELISA a Chiron-Ortho recombi-
nant immunoblot assay (RIBA) was performed in anti-HCV
reactive samples. The RIBA test includes the three recombi-
nant antigens, superoxide dismutase, 5-1-1 polypeptide synthe-
sized in Escherichia coli, and C-100-3 synthesized in yeast,
applied in a nitrocellulose strip. Only samples reactive with
both 5-1-1 and C-l00-3 were considered to be positive, and
those reactive with only one of the HCV antigens were inde-
terminate [23].
Hepatitis B markers, including HBsAg, anti-HBc and anti-
HBs, were assayed by radioimmunoassay using commercially
available kits (Sorin Biomedica).
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Table 1. Characteristics of the 67 kidney recipients according to their
anti-HCV status at the kidney transplant time
Anti-HCV Anti-HCV
positive negative(N = 32) (N = 35) Pvalue
Male % 68.7 74.2 NS
Ageyears(X±sD) 39±14 40±14 NS
Time on dialysis months 77 43 52 39 <0.01
(X SD)
Blood transfused units 15 13 8 4 <0.05
Hepatitis B serology
HB5Ag (% positive) 9.3 8.6 NS
Anti-HBc (% positive) 36.0 23.6 NS
Anti-HBs (% positive) 36.0 23.6 NS
Liver disease at dialysis
Acute hepatitis (N) 5 5
Chronic hepatitis (N) 12 1 < 0.00l
None (N) 15 29
a With respect to No liver disease
The following variables for each patient were ascertained
from the medical records at the time of collecting the blood
sample for anti-HCV testing in November 1989: sex, age,
duration of dialysis, number of blood units transfused, duration
of transplantation follow-up, type of immunosuppression, se-
rum creatinine level, presence of liver disease and status related
to HBV. None admitted to a history of intravenous drug abuse.
Liver disease was considered to be present when serum
transaminase activity and/or cholestasis enzymes were twice
the upper limit of normal values or higher in, at least, two
consecutive determinations. Liver biopsy was performed in
only four patients, therefore diagnosis of liver disease was
based on clinical and biochemical data. Liver disease was
considered acute or chronic according to the duration of the
biochemical abnormalities (less or more than six months). At
the end of 1990 medical charts were again reviewed to obtain
information on the kidney allografts and patient survival.
Statistical analysis
Chi square test with a Yates' correction factor and the
Student's t-test were used for statistical analysis of the univari-
ate variables. A multiple logistic regression analysis was per-
formed using the BMDP program with anti-HCV positivity as
the dependent variable, and the duration of hemodialysis treat-
ment and the amount of blood transfused as predictor variables.
Results
Prevalence of anti-HCV before kidney transplantation
Of the 67 patients analyzed, 32 (48%) were positive for
anti-HCV at kidney transplant time. Seropositive and seroneg-
ative patients were not significantly different with regards to the
age, sex, and HBV marker seropositivity, but differed with
respect to the time on hemodialysis (77 43 vs. 52 39
months, P < 0.01) and the number of blood units transfused (15
13 vs. 8 4, P < 0.05; Table 1). In the logistic regression
analysis only the number of blood transfusions was associated
with an independent risk for anti-HCV positivity.
Ten patients had a history of resolving hepatitis during their
stay in the hemodialysis unit, and 13 had a chronic liver disease
Table 2. Relationship between the ELISA ratios of anti-HCV in
patients submitted to kidney transplantation and the number of units
of blood transfused
Units of
blood
ELISA ratio of antiHCVa
At time of
transplantation
Following
transp1antation'
<5
8—10
11—20
> 20
1.72 2.94
3.38 3.59
3.76 3.46
5.64 2.58
0.98 1.77
1.67 2.67
3.13 3.27
3.20 2.64
a The optical densities (OD) were measured by the Anthos reader
2001 (Ortho Diagnostics) with a limit value of 3000 nm. When the
measure of an individual case overflowed the reading limit, we calcu-
lated the ELISA ratio taking as the numerator the limit value.
b The anti-HCV testing was done at an average of 32 20 months
following transplantation.
which persisted at the time of transplantation. Anti-HCV was
found to be positive in 92% of the latter compared with 50% of
the former patients. Anti-HCV was also positive in 15 (32%) of
those patients without overt liver disease (Table 1).
The ELISA ratio of positive samples increased with the
increasing number of blood units transfused (Table 2), but no
differences were found in the ELISA ratio of serum samples
from patients with and without overt liver disease (data not
shown).
Thirty ELISA reactive samples were RIBA reactive, one
indeterminate and one negative.
Prevalence of anti-HCV following kidney transplantation
Anti-HCV were still positive in 23 (72%) of the 32 patients who
were seropositive at time of transplant, when we examined them
27 19 months after transplantation, but nine (28%) of these
patients had become negative, one of them was RIBA negative
pre-transpiant and another indeterminate. For patients who had
seroreversion the interval between the two serum samplings for
anti-HCV testing was longer than in those who remained positive
(37 20 vs. 27 19 months, P = 0.08), and the ELISA ratio of
serum samples collected at transplant time was lower (4.8 2.7
vs. 6.9 0.6, P <0.01). Neither age, duration of hemodialysis
therapy, amount of blood transfused, nor the presence or absence
of liver disease correlated with seroreversion.
Among the 35 patients who were anti-HCV negative at
transplantation, 30 (86%) remained negative and 5 (14%) sero-
converted. All but one of the latter developed liver disease
during the post-transplantation follow-up. The remaining case
had a resolving acute hepatitis before transplantation. Patients
who seroconverted to anti-HCV positive had received a signif-
icantly higher number of blood units than patients who re-
mained seronegative (13 6 vs. 7 4, P < 0.005). Ten (66.6%)
of the 15 patients without overt liver disease who were anti-
HCV positive at the time of transplantation developed raised
serum transaminase activity shortly following transplantation,
but none had symptoms of liver disease during follow-up.
The frequency of graft rejection episodes, the type of immu-
nosuppressive therapy, the degree of renal impairment and the
mortality rate during follow-up were unrelated to the anti-HCV
status at the time of transplantation (Table 3).
Fourteen kidney recipients had suffered from an episode of
acute hepatitis and 25 had chronic liver disease. Anti-HCV was
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Table 3. Kidney graft morbidity and patient mortality according to
the anti-HCV status at the time of transplantation
Anti-HCV Anti-HCV
positive negative(N=32) (N=35)
Mean episodes of rejection per 1.20 1.26
patient
Patients with episodes of graft 24 (74%) 23 (65%)
rejection
Serum creatinine (1989) mg/dL 2.08 1.06 1.78 0.64
Serum creatinine (1990) mg/dL 1.92 0,8 1.77 0.96
Patients dead 1 (3.1%) 1 (2.8%)
Average follow-up months 30 33
detected in three (2 1%) of the former and in 14 (56%) of the
latter. Eleven (39%) of the 28 patients without overt liver
disease were anti-HCV positive. ELISA ratios were higher in
patients with liver disease than in those without (2.3 2.9 vs.
1.2 2.2, P = 0.08).
Discussion
The present study demonstrates that HCV infection is wide-
spread in hemodialysis patients undergoing kidney transplanta-
tion and in kidney recipients. The prevalence of anti-HCV was
48% at time of transplantation and 42% following transplanta-
tion. These rates of prevalence are two to three times those
reported from hemodialysis units in United States (15.6%) [20],
Germany (18.4%) [24], and Italy (28.6%) [18]. Several reasons
may account for these differences, Firstly, patients who are
going to be transplanted are more likely to be exposed to HCV
because they have been on dialysis longer and have been more
heavily transfused than patients screened in other hemodialysis
units. The serological survey of 178 patients undergoing main-
tenance hemodialysis in our hospital during February 1990
showed an anti-HCV prevalence of 30%, which is closer to that
found in other European countries [18, 24].
Secondly, the chances for acquiring post-transfusion hepati-
tis C are related to the prevalence of anti-HCV in blood donors
of the same area. This prevalence was 1.2% among blood
donors in Barcelona in 1989 [17], but it was much higher (2.2%)
in the serum samples from donors included in a study of
post-transfusion hepatitis conducted in our hospital from 1982
to 1985 [25], when blood donors from high risk groups for
acquired human immunodeficiency syndrome were not ex-
cluded. Thus, patients submitted to blood transfusions in earlier
years were subject to a higher risk than those transfused later.
Lastly, an undetected higher than usual exposure to HCV could
have occurred in our hemodialysis unit as a result of break-
downs in infection control procedures.
Patients who were seropositive for anti-HCV had received a
higher number of blood transfusions than those seronegative,
suggesting that blood transfusions are the most important
mechanism for HCV transmission in hemodialysis units [20].
The finding of a correlation between the ELISA ratio of
anti-HCV positive samples and the amount of blood transfused
suggests an effect of recurrent exposures to the virus on the
humoral immune response. In our series the multiple regression
logistic analysis showed a statistically significant relationship
between anti-HCV seropositivity and the number of blood
transfusions, but not with the duration of hemodialysis. How-
ever, modes of HCV transmission other than blood transfusions
in the hemodialysis setting cannot be excluded, since an anti-
HCV prevalence higher than in the general population was
found in non-transfused hemodialysis patients [26—28].
The assumption that HCV infection is the main etiology of
chronic liver disease in patients on hemodialysis, since a policy
for hepatitis B erradication has been successfully introduced in
most units [29], has been confirmed in this study. Anti-HCV
was detected at the time of transplantation in 92% of patients
with persistently abnormal liver function tests and in 50% of
those with a history of resolving hepatitis. In the remaining
patients anti-HCV was not found, either because it became
undetectable or because the hepatitis was due to another virus
or to a non-viral cause.
Particularly striking was the finding of anti-HCV in 39% of
patients with normal liver function tests when submitted to
kidney transplantation. This is difficult to interpret, since we
cannot distinguish with the presently available ELISA anti-
HCV assay, between present and past HCV infections. False-
positive results are unlikely because RIBA was positive in all
but two ELISA reactive samples. We favor the hypothesis that
many of these anti-HCV carriers were indeed infected before
transplantation, because we observed the development of liver
disease without acute onset within the first weeks following
kidney transplantation in two thirds of patients who had normal
serum transaminase activity before transplantation, thus sug-
gesting that liver disease was already present, although bio-
chemically silent. This is in keeping with the finding by Degos et
al [30] regarding histologic changes of chronic hepatitis in liver
biopsies obtained during the kidney transplantation procedure
from patients with no biochemical evidence of liver disease.
Thus, diagnosis of liver disease cannot rely on elevation of
serum transaminases in hemodialysis patients, as this elevation
may diminish due to either the dialysis of the enzyme or to
pyridoxine deficiency [31, 32].
Kidney transplant recipients have a lower prevalence of
anti-HCV than hemodialysis patients, since anti-HCV were
only detected in 21% of our patients who had acute hepatitis
following transplantation and in 56% of those with chronic liver
disease. Loss of anti-HCV occurred in 28% of our kidney
transplant recipients who were anti-HCV positive at time of
transplantation, and this was related to a longer follow-up
period. In some of these cases a prior healed hepatitis C could
explain the disappearance of antibodies [33], but the effect of
the immunosuppressive drugs may be an alternative explana-
tion, since ELISA ratios decreased in all anti-HCV positive
patients following transplantation. The lack of new exposures
to HCV as the result of suppression of blood transfusions could
also account for a reduction in the amount of circulating
antibodies. The long-term persistence of anti-HCV after trans-
plantation may indicate a chronic carrier status, particularly in
those patients with raised levels of serum transaminases.
Of the 35 anti-HCV negative patients at the time of transplan-
tation, five (14%) seroconverted. They probably became in-
fected through blood transfusions because the 14% seroconver-
sion rate is close to the 16 to 17% incidence of non-A, non-B
post-transfusion hepatitis found in several prospective studies
in Spain [25, 34, 35]; yet the role of an HCV infected graft
cannot be excluded. Screening of blood and organ donors for
anti-HCV is likely to decrease the incidence of HCV infection
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in kidney recipients in the future. The risk of cross infection in
hemodialysis units must also be investigated.
Due to the nature of the study we have no data on the
morbidity and liver-related mortality of patients who were
anti-HCV positive before kidney transplantation. Nevertheless,
the similarity between anti-HCV positive and negative patients
with regard to the frequency and severity of graft-rejection
episodes and to the long-term mortality suggests that ELISA
anti-HCV positivity should not be considered as a contraindi-
cation for kidney transplantation.
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